Skip to content

Comparison between the effect of Rosuvastatin and Orlept (Sodium Valproate) in Decrease of migraine headaches

Comparison between the effect of Rosuvastatin and Orlept (Sodium Valproate) in Decrease of migraine headaches

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT20180114038369N1
Enrollment
40
Registered
2018-03-18
Start date
2018-01-30
Completion date
Unknown
Last updated
2018-03-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Migraine headaches. Migraine

Interventions

Intervention 1: Intervention group: Treatment in Group 1 using sodium valproate. Intervention 2: Intervention group: Treatment in group two using rosuvastatin tablets.

Sponsors

Ghoum University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
20 Years to 70 Years

Inclusion criteria

Inclusion criteria: Those who have not received sodium valproate within the last six month. Have migraine headaches With or Without a up to 6 month before this study Confirmation of the presence of migraine by the neurologist There are more than 4 month of attack Have two or more headache attacks over the past 3 month

Exclusion criteria

Exclusion criteria: Patients with mental illness Patients with systemic and background diseases such as diabetes, liver or malignant diseases Pregnant and Lactating women Desire to quit of this study See incidence of complications

Design outcomes

Primary

MeasureTime frame
Migraine headache. Timepoint: Follow up these Patient will be done for 3 months. Method of measurement: The severity of migraine headache is measured by the Visual Analogue Scale (VAS).

Countries

Iran (Islamic Republic of)

Contacts

Public ContactReyhaneh Tabaraei

Ghoum University of Medical Sciences

rtabaraii@muq.ac.ir+98 25 3107 1300

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026